Brief Summary
This study aims to evaluate the feasibility and benefits of molecular screeningtesting for cancer or conditions that can lead to cancer before symptoms appear, also known as cancer screening in participants with haematological malignancies.
Intervention/Treatment
- Nil.
Inclusion Criteria
- Participants, aged 18 years and older, with pathologically confirmed bloodthe red bodily fluid that transports oxygen and other nutrients around the body cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs at initial diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results or relapsethe return of disease/refractory disease.
- Sufficient and accessible tissuea group of cells that work together to perform a function for molecular screening.
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) performance status 0, 1 or 2.
- Willing and potentially able to comply with study requirements.
- Signed, written informed consenta process in which a patient receives detailed information about a procedure or treatment, including its potential risks, benefits, and alternatives. The patient then has the opportunity to understand the information and voluntarily agree to the procedure or treatment. to participation in the molecular screening.